drugset / Trial / NCT00250120

Pharmacology Study of Aerosolized Liposomal

NCT00250120

Phase 2 Withdrawn University of New Mexico
Non-randomizedSingle-groupOpen-labelTreatment

Summary

To determine the overall response rate to liposomal 9-Nitro-20 (S)-Camptothecin (L9NC) administered by aerosolization in patients with non-small-cell lung cancer (any stage). To determine toxicity profile of L9NC administered by aerosolization for 5 consecutive days per week X 8 weeks, every 10 weeks. To perform a pharmacology study of L9NC in the plasma, and the lungs after aerosolization. A specific protocol will be written for this part.

Timeline

Start
2003-04
Primary completion
2007-03
Completion
2007-08

Drugs

EvaluationDrugModalityDoseRoute
Subject rubitecan Unknown 0.52 mg/m2 Inhaled

Indications